Susquehanna International Group, LLP Ocugen, Inc. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.98 - $1.95 $78,008 - $155,220	-79,600 Reduced 81.72%	17,800 $17,000
Q2 2024 Aug 15, 2024	BUY	$1.18 - $1.98 $97,586 - $163,746	82,700 Added 562.59%	97,400 $150,000
Q1 2024 May 07, 2024	BUY	$0.5 - $1.83 $900 - $3,294	1,800 Added 13.95%	14,700 $24,000
Q4 2023 Feb 14, 2024	BUY	$0.36 - $0.57 $144 - $227	400 Added 3.2%	12,900 $7,000
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.62 $1,120 - $1,736	-2,800 Reduced 18.3%	12,500 $5,000
Q2 2023 Aug 11, 2023	SELL	$0.45 - $0.88 $14,535 - $28,424	-32,300 Reduced 67.86%	15,300 $8,000
Q1 2023 May 16, 2023	SELL	$0.82 - $1.33 $44,690 - $72,485	-54,500 Reduced 53.38%	47,600 $40,000
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.87 $213,120 - $359,040	-192,000 Reduced 65.28%	102,100 $132,000
Q3 2022 Nov 14, 2022	SELL	$1.75 - $3.1 $221,025 - $391,530	-126,300 Reduced 30.04%	294,100 $523,000
Q2 2022 Aug 15, 2022	SELL	$1.83 - $3.45 $309,087 - $582,705	-168,900 Reduced 28.66%	420,400 $954,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $477,360 - $962,880	-204,000 Reduced 25.72%	589,300 $1.95 Million
Q4 2021 Feb 14, 2022	SELL	$4.38 - $15.67 $5.06 Million - $18.1 Million	-1,155,400 Reduced 59.29%	793,300 $3.61 Million
Q3 2021 Nov 15, 2021	BUY	$6.36 - $8.51 $3.93 Million - $5.26 Million	618,400 Added 46.49%	1,948,700 $14 Million
Q2 2021 Aug 11, 2021	BUY	$5.52 - $15.68 $4.81 Million - $13.7 Million	871,400 Added 189.89%	1,330,300 $10.7 Million
Q1 2021 May 17, 2021	BUY	$1.66 - $15.81 $761,774 - $7.26 Million	458,900 New	458,900 $3.12 Million

125

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $204M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.